loading
Schlusskurs vom Vortag:
$16.35
Offen:
$16.54
24-Stunden-Volumen:
654.41K
Relative Volume:
1.17
Marktkapitalisierung:
$993.94M
Einnahmen:
$1.23M
Nettoeinkommen (Verlust:
$-214.90M
KGV:
-4.0003
EPS:
-4.1222
Netto-Cashflow:
$-151.25M
1W Leistung:
+7.71%
1M Leistung:
+9.86%
6M Leistung:
-24.43%
1J Leistung:
-46.43%
1-Tages-Spanne:
Value
$16.16
$16.73
1-Wochen-Bereich:
Value
$15.44
$17.18
52-Wochen-Spanne:
Value
$10.91
$40.26

Spyre Therapeutics Inc Stock (SYRE) Company Profile

Name
Firmenname
Spyre Therapeutics Inc
Name
Telefon
(617) 651-5940
Name
Adresse
221 CRESCENT STREET, WALTHAM
Name
Mitarbeiter
65
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
SYRE's Discussions on Twitter

Vergleichen Sie SYRE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SYRE
Spyre Therapeutics Inc
16.49 924.01M 1.23M -214.90M -151.25M -4.1222
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-08 Eingeleitet Leerink Partners Outperform
2025-03-18 Eingeleitet Wolfe Research Outperform
2024-09-04 Eingeleitet Wedbush Outperform
2024-07-16 Eingeleitet Evercore ISI Outperform
2024-05-02 Eingeleitet Robert W. Baird Outperform
2024-03-01 Hochstufung Wells Fargo Equal Weight → Overweight
2023-12-20 Eingeleitet BTIG Research Buy
2023-12-11 Eingeleitet Guggenheim Buy
2023-12-11 Eingeleitet Jefferies Buy
2020-05-04 Eingeleitet Piper Sandler Overweight
2019-03-21 Eingeleitet JP Morgan Overweight
2018-09-04 Herabstufung Wells Fargo Outperform → Market Perform
2018-04-24 Eingeleitet Evercore ISI Outperform
2018-03-14 Bestätigt Needham Buy
Alle ansehen

Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten

pulisher
Jul 22, 2025

Is Spyre Therapeutics Inc. a good long term investmentExplosive earnings growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Spyre Therapeutics Inc. Stock Analysis and ForecastMarket-beating returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Spyre Therapeutics Inc. stockTremendous growth potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Spyre Therapeutics Inc. stock priceFree High-Return Strategy Alerts - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 20, 2025

Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Target Price at $53.40 - Defense World

Jul 20, 2025
pulisher
Jul 16, 2025

Why Spyre Therapeutics Inc. stock attracts strong analyst attentionMomentum Swing Watchlist - beatles.ru

Jul 16, 2025
pulisher
Jul 15, 2025

How Spyre Therapeutics Inc. stock performs during market volatilityPredictable High Return Trades - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Spyre Therapeutics Inc. stock price move sharplyPotential Rocket List - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Here's Why We're Not Too Worried About Spyre Therapeutics' (NASDAQ:SYRE) Cash Burn Situation - Yahoo Finance

Jul 15, 2025
pulisher
Jul 03, 2025

Spyre Therapeutics Announces Grants of Inducement Awards - TradingView

Jul 03, 2025
pulisher
Jun 26, 2025

GAMMA Investing LLC Purchases New Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 26, 2025
pulisher
Jun 23, 2025

Analysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and Spyre Therapeutics (SYRE) - The Globe and Mail

Jun 23, 2025
pulisher
Jun 18, 2025

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward (SYRE) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 17, 2025

Spyre reports results from early stage TL1A antibody trials (SYRE) - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

Transcript : Spyre Therapeutics, Inc.Special Call - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Spyre Therapeutics Announces Positive Interim Phase 1 Results fo - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Spyre Therapeutics Says Anti-TL1A Antibodies Met Objectives in Interim Phase 1 Study - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Spyre Therapeutics Announces Positive Phase 1 Results - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Spyre Therapeutics (SYRE) Advances Clinical Trials with Encouraging Interim Results | SYRE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts - PR Newswire

Jun 17, 2025
pulisher
Jun 16, 2025

Spyre Therapeutics to Host Conference Call and Webcast to Report - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Spyre Therapeutics to Unveil First Human Trial Data for Revolutionary IBD Antibody Treatment - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

Bank of America Corp DE Reduces Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 16, 2025
pulisher
Jun 11, 2025

California State Teachers Retirement System Grows Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 22,540 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Transcript : Spyre Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09 - MarketScreener

Jun 09, 2025
pulisher
Jun 06, 2025

Spyre Therapeutics Announces Grants of Inducement Awards | SYRE Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Spyre Therapeutics Expands Team with Strategic Stock Options Worth $773K to Three Key Hires - Stock Titan

Jun 06, 2025
pulisher
Jun 06, 2025

Squarepoint Ops LLC Purchases 6,754 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Jun 06, 2025
pulisher
Jun 04, 2025

Transcript : Spyre Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 08 - marketscreener.com

Jun 04, 2025
pulisher
Jun 03, 2025

Guggenheim reiterates Buy rating on Spyre stock citing pipeline progress By Investing.com - Investing.com Canada

Jun 03, 2025
pulisher
May 30, 2025

Spyre Therapeutics to Participate in Upcoming June Investor Conferences - Eastern Progress

May 30, 2025
pulisher
May 30, 2025

Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know - sharewise

May 30, 2025

Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):